Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 2/20 | 0.51 |
| ▸ | PRKCI | P41743 | 2/20 | 0.51 |
| ▸ | JAK2 | O60674 | 13/20 | 0.39 |
| ▸ | JAK3 | P52333 | 12/20 | 0.39 |
| ▸ | JAK1 | P23458 | 11/20 | 0.39 |
| ▸ | TYK2 | P29597 | 5/20 | 0.38 |
| ▸ | MGLL | Q99685 | 2/20 | 0.38 |
| ▸ | TTBK1 | Q5TCY1 | 2/20 | 0.36 |
| ▸ | TTBK2 | Q6IQ55 | 2/20 | 0.36 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1154546 | 1.00 | AXL (0.51) | AXLPRKCIJAK2JAK3JAK1 | |
| SCHEMBL1154763 | 0.81 | AXL (0.54) | AXLPRKCIJAK2JAK3JAK1 | |
| SCHEMBL29713778 | 0.81 | AXL (0.54) | AXLPRKCIJAK2JAK3JAK1 | |
| SCHEMBL12876261 | 0.81 | AXL (0.54) | AXLPRKCIJAK2JAK3JAK1 | |
| SCHEMBL13417647 | 0.78 | AXL (0.50) | AXLPRKCIJAK2JAK3JAK1 | |
| SCHEMBL1154022 | 0.76 | AXL (0.56) | AXLPRKCIJAK2JAK3JAK1 | |
| SCHEMBL12653267 | 0.76 | NUDT1 (0.49) | AXLPRKCIJAK2JAK3JAK1 | |
| SCHEMBL12618980 | 0.76 | NUDT1 (0.49) | AXLPRKCIJAK2JAK3JAK1 | |
| SCHEMBL28735132 | 0.76 | AXL (0.56) | AXLPRKCIJAK2JAK3JAK1 | |
| SCHEMBL29588238 | 0.76 | AXL (0.56) | AXLPRKCIJAK2JAK3JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110039822-A1 | HETEROCYCLIC JANUS KINASE 3 INHIBITORS | ASTELLAS PHARMA INC. (JP) | 2011-02-17 | — | — | US | disclosed |
| US-20100105661-A1 | CONDENSED PYRIDINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-04-29 | — | — | US | disclosed |
| EP-2123651-A1 | CONDENSED PYRIDINE COMPOUND | Astellas Pharma Inc. (JP) | 2009-11-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105661-A1 | CONDENSED PYRIDINE COMPOUND | JAK3, IRAK3, JAK1 | AXL 1838/4885PRKCI 1051/4885JAK2 5/4885 |
| US-20110039822-A1 | HETEROCYCLIC JANUS KINASE 3 INHIBITORS | JAK3, JAK1, JAK2 | AXL 973/4885PRKCI 340/4885JAK2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.